ReviewJournal of clinical hypertension (Greenwich, Conn.)
The economic impact of hypertension.
Review in Journal of clinical hypertension (Greenwich, Conn.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 114 citations in OpenAlex.
- Prescribing Data in General Practice Demonstration (PDGPD) project--a cluster randomised controlled trial of a quality improvement intervention to achieve better prescribing for chronic heart failure and hypertension.BMC health services research · 2012Trial
- Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- Hypertension due to financial mismanagement.Frontiers in public health · 2026Article
- Application of hypertension clinical guidelines among family medicine doctors in primary health care centers in Riyadh City, Saudi Arabia.Journal of family medicine and primary care · 2025Article
- Trends in hypertension prevalence, control, and antihypertensive use in England from 2003 to 2021: insights from annual, nationwide Health Surveys for England.BMJ medicine · 2025Article
- The Association of Iron Intake and Hypertension, Does Iron Intake Decrease Blood Pressure?Cardiovascular toxicology · 2024Article
- Assessment of hypertension service availability in some primary health centres in Nigeria: a mixed-methods study.BMJ open · 2023Article
- Productivity-adjusted life-years and correlates of uncontrolled hypertension at two health facilities in Zambia.PloS one · 2023Article
- Article
- National and regional prevalence rates of hypertension in Saudi Arabia: A descriptive analysis using the national survey data.Frontiers in public health · 2023Article
- Hypertension in the South African public healthcare system: a cost-of-illness and burden of disease study.BMJ open · 2022Article
- An Assessment of the Knowledge and Practices of Adults in Jazan, Saudi Arabia, Concerning Routine Medical Checkups.Patient preference and adherence · 2022Article
- The cost-effectiveness of pharmacist-physician collaborative care models vs usual care on time in target systolic blood pressure range in patients with hypertension: a payer perspective.Journal of managed care & specialty pharmacy · 2021Article
- Gender Differences in The Factors associated with Hypertension in Non-Diabetic Saudi Adults-A Cross-Sectional Study.International journal of environmental research and public health · 2021Article
- Article
- Association of Hypertension and Lipid Profile with Osteoporosis.Scientifica · 2020Article
- Descriptive Cross-Sectional Study on Knowledge, Awareness, and Adherence to Medication among Hypertensive Patients at a Tertiary Care Centre in Colombo District, Sri Lanka.International journal of hypertension · 2020Article
- The Cost-Effectiveness of an Intervention Program to Enhance Adherence to Antihypertensive Medication in Comparison With Usual Care in Community Pharmacies.Frontiers in pharmacology · 2019Article
- Prevalence of hypertension and prehypertension and its associated cardioembolic risk factors; a population based cross-sectional study in Alkharj, Saudi Arabia.BMC public health · 2018Article
- Recent Research and Developing Trends of Wearable Sensors for Detecting Blood Pressure.Sensors (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High blood pressure is the most common chronic medical problem prompting visits to primary health care providers, yet it is estimated that only 34% of the 50 million American adults with hypertension have their blood pressure controlled to a level of <140/90 mm Hg. Thus, about two thirds of Americans with hypertension are at increased risk for cardiovascular events. The medical, economic, and human costs of untreated and inadequately controlled high blood pressure are enormous. Adequate management of hypertension can be hampered by inadequacies in the diagnosis, treatment, and/or control of high blood pressure. Health care providers face many obstacles to achieving blood pressure control among their patients, including a limited ability to adequately lower blood pressure with monotherapy and a typical reluctance to increase therapy (either in dose or number of medications) to achieve blood pressure goals. Patients also face important challenges in adhering to multidrug regimens and accepting the need for therapeutic lifestyle changes. Nonetheless, the achievement of blood pressure goals is possible, and, most importantly, lowering blood pressure significantly reduces cardiovascular morbidity and mortality, as proved in clinical trials. The medical and human costs of treating preventable conditions such as stroke, heart failure, and end-stage renal disease can be reduced by antihypertensive treatment. The recurrent and chronic morbidities associated with hypertension are costly to treat. Pharmacotherapy for hypertension therefore offers a substantial potential for cost savings. Pharmacoeconomic analyses regarding antihypertensive drug therapies, their costs, and the relevant reductions in health care expenditures are a useful framework for optimizing current strategies for hypertension management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.